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LETTERS TO THE EDITOR
 
To the Editor—While I would agree with the editor’s
comments in this issue of Value in Health (Pharmaco-
economic Guidelines: Where Do We Go from Here?)
that the societal perspective is best aligned with maxi-
mizing social welfare, I would argue that other per-
spectives are important in expanding the use and ap-
plication of pharmacoeconomic analyses.
I have argued elsewhere that the limited applica-
tion of cost-effectiveness analysis (CEA) is partly de-
rived from a misunderstanding that it can only in-
form decision making, not provide a criterion for
technology adoption or resource allocation [1].
Properly performed, CEA identifies critical assump-
tions, areas of uncertainty, and the key factors that
determine whether a technology or pharmaceutical
agent provides value. However, it does not address
other important issues that must be incorporated
into resource allocation decisions, such as the distri-
butional consequences of alternative choices. There-
fore, it must be embedded within an administrative
framework that promotes confidence in the social
justice of health care decision making.
Providing decision makers with pharmacoeco-
nomic analyses that adopt their perspectives is an
important strategy to enhance their uptake and use.
For example, my colleagues and I recently exam-
ined the indirect cost of ischemic heart disease from
the employer perspective [2]. This analysis showed
that the indirect costs are overwhelmingly a result
of morbidity costs; this contrasts with the societal
perspective, where they are largely a result of mor-
tality costs. This report should provide greater in-
centive for employers to view provision of health
benefits not just as a business expense but as invest-
ment in their human capital—an argument that
may be more persuasive than that for enhancing
social welfare.
As was noted in the accompanying editorial [3],
“Texts on cost-effectiveness analysis . . . remind
researchers to . . . select the perspective of the
decision maker who will use the analysis.” The ad-
monition is an outgrowth of the purpose for analy-
sis of cost of illness, cost-effectiveness, and cost ben-
efit; a tool to improve resource allocation. Whether
properly performed or not, pharmacoeconomic
analyses (regardless of perspective) can be used to
justify resource allocation decisions driven by other
considerations, such as financial constraints. Re-
quiring that analyses be performed from a societal
perspective is a rather weak counter measure. In-
stead, we need to focus on transparency of decision
making and administrative processes that ensure
the deliberative nature and legitimacy of health care
decision making.—Marc Berger, MD, Merck &
Company, West Point, PA.
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